We hypothesize that the presentation of multiple TBG ligands on the surface of the nanocapsule promotes cancer cell specificity [46], which was demonstrated by the accumulation of s50-TBG nanocapsules in epithelial tumor cells within bone, with no observed accumulation or binding in non-transformed bone cells or other tissues such as liver, spleen or kidney. The gene discussed is SERPINA7; the disease is cancer.